The German drug developer, 4SC AG, has announced plans to raise up to €29 million from its existing shareholders in order to finance the acquisition of eight oncology projects from Nycomed, a privately-owned, Zurich-based pharmaceutical company.
The German drug developer, 4SC AG, has announced plans to raise up to €29 million from its existing shareholders in order to finance the acquisition of eight oncology projects from Nycomed, a privately-owned, Zurich-based pharmaceutical company.